Hidroxicloroquina como
alternativa para o tratamento da infecção causada pelo SARS-CoV-2
O
que se sabe até agora?
A síndrome respiratória
aguda grave causada pelo coronavírus 2 (SARS-CoV-2) tem alertado a população
para as elevadas taxas de morbidade e mortalidade, levando a Organização Mundial de Saúde (OMS) a declarar
emergência de saúde pública em 2020. Nesse cenário, pesquisas estão sendo
amplamente realizadas na busca de tratamentos eficazes contra a infecção.
Dentre estes, antivirais
têm sido testados, a hidroxicloroquina (HCQ), que tem apresentado resultados interessantes
na redução da carga viral.
Nesse sentido, o objetivo
deste trabalho é descrever o potencial da HCQ frente à infecção por SARS-CoV-2
descrito na literatura.
A HCQ consegue reduzir a
carga viral impedindo a entrada do coronavírus na célula hospedeira.
No entanto, esses
resultados não garantem a sua utilização devido à necessidade de maiores
estudos que comprovem a eficácia clínica e segurança na administração da HCQ em
pacientes com COVID-19.
Referencias:
ABDULAZIZ, N.; SHAH, A. R.; MCCUNE, W. J.
Hydroxychloroquine: balancing the need to maintain therapeutic levels with
ocular safety: an update. Clinical Therapeutics, v. 30, n.3, p. 249-255, 2018.
BANSAL, M. Cardiovascular disease and COVID-19.
Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020.
BEN-ZVI, I.; KIVITY, S.; LANGEVITZ, P.; SHOENFELD, Y.
Hydroxychloroquine: from malaria to autoimmunity. Clinical Reviews in Allergy
& Immunology, v. 42, n. 2, p. 145-153, 2012.
BHUSHAN, P.; AGGARWAL, A.; BALIYAN, V. Complete
clearance of cutaneous warts with hydroxychloroquine: Antiviral action?. Indian
Journal of Dermatology, v. 59, n. 2, p. 211, 2014.
BOGACZEWICZ, A.; SOBÓW, T. Psychiatric adverse effects
of chloroquine. Psychiatria i Psychologia Kliniczna, v. 17,
n. 2, p. 111-114, 2017.
BRASIL. Ministério da
Saúde. Doença pelo Coronavírus 2019. Boletim Epidemiológico 12 – COE COVID-19 –
19 de abril de 2020. Disponível em: https://portalarquivos.saude.gov.br/images/pdf/2020/April/19/BE12-Boletim-do-COE.pdf
Acesso em: 19/04/2020.
BROWNING, D. J. Pharmacology of Chloroquine and
Hydroxychloroquine. In: Hydroxychloroquine and Chloroquine Retinopathy.
Springer, New York, 2014. P. 35-63.
CALY, L. et al. The FDA-approved Drug Ivermectin
inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, p. 104787,
2020.
CANSU, D. U.; KORKMAZ, C. Hypoglycaemia induced by
hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology, v.
47, n. 3, p. 378-379, 2008.
CHATRE, C. et al. Hydroxichloroquine: A Systematic
Review of the Literature. Drug Saf, v. 41, n. 10, p. 919-931, 2018.
CHIANG, E.; JAMPOL L. M.; FAWZI. Retinal toxicity
found in a patient with systemic lupus erythematosus pior to 5 years of
treatment with hydroxychloroquine. Rheumatology (Oxford), v. 53, n. 11, p.
2001-2001, 2014.
CHOY, K. T. et al. Remdesivir, lopinavir, emetine, and
homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Research,
p. 104786, 2020.
CHU, H. et al. Comparative replication and immune
activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study
with implications for the pathogenesis of COVID-19. Clinical Infectious
Diseases, 2020.
CUI, J; LI, F; SHI, Z. Origin and evolution of
pathogenic coronaviruses. Nature Reviews Microbiology, v. 17, n. 3, p. 181-192,
2019.
CHANNAPPANAVAR, R. et al. Dysregulated type I interferon
and inflammatory monocyte-macrophage responses cause lethal pneumonia in
SARS-CoV-infected mice. Cell Host & Microbe, v. 19, n. 2, p. 181-193, 2016.
CHONG, P. Y. et al. Analysis of deaths during the
severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in
determining a SARS diagnosis. Archives of Pathology & Laboratory Medicine,
v.128, n.2, p.195-204, 2004.
DEVAUX, C. A. et al. New insights on the antiviral
effects of chloroquine against coronavirus: what to expect for COVID-19?.
International journal of antimicrobial agents, p. 105938, 2020.
ELFIKY, ABDO A. Ribavirin, Remdesivir, Sofosbuvir,
Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase
(RdRp): A molecular docking study. Life Sciences, p. 117592, 2020.
GAUTRET, P. et al. Hydroxychloroquine and azithromycin
as a treatment of COVID-19: results of an open-label non-randomized clinical
trial. International Journal of Antimicrobial Agents, p. 105949, 2020.
GIANFRANCESCO, M. A. et al. Hydroxychloroquine dosing
in immune-mediated diseases: implications for patient safety. Rheumatology
International, v. 37, n. 10, p. 1611-1618, 2017.
JEON, S. et al. Identification of antiviral drug
candidates against SARS-CoV-2 from FDA-approved drugs. bioRxiv, 2020.
LIPSITCH, M.; SWERDLOW, D. L.; FINELLI, L. Defining
the epidemiology of Covid-19—studies needed. New England Journal of Medicine,
2020.
KIM, J. M. et al. Identification of Coronavirus
Isolated from a Patient in Korea with COVID-19. Osong Public Health and Research
Perspectives, v. 11, n. 1, p. 3, 2020.
KUMAR, A. et al. Hydroxychloroquine inhibits Zika
virus NS2B-NS3 protease. ACS Omega, v. 3, n. 12, p. 18132-18141, 2018.
LAI, CHIH-CHENG et al. Severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):
the epidemic and the challenges. International journal of antimicrobial agents,
p. 105924, 2020.
LAKKIREDDY, D. R. et al. Guidance for Cardiac
Electrophysiology During the Coronavirus (COVID-19) Pandemic from the Heart
Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American
College of Cardiology; and the Electrocardiography and Arrhythmias Committee of
the Council on Clinical Cardiology, American Heart Association. Heart Rhythm,
2020.
LI, Z. et al. Development and clinical application of
a rapid IgM‐IgG
combined antibody test for SARS‐CoV‐2 infection diagnosis. Journal of Medical Virology,
2020.
LIU, J. et al. Hydroxychloroquine, a less toxic
derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in
vitro. Cell Discovery, v. 6, n. 1, p. 1-4, 2020.
MADJID, M.; NAEINI, P. S.; SOLOMON, S. D. Potential
effects of coronaviruses on the cardiovascular system a review. JAMA
Cardiology, 2020.
MARDONES, P. S. et al. Hypoglycemina due to
hydroxychloroquine, an uncommon association but to keep in mind, case report
and review of literature. Journal of Diabetes, Metabolic Disorders &
Control, v. 7, n. 1, p. 6-7, 2020.
MARMOR, M. F. et al. Recommendations on Screening for
Chloroquine and Hydroxychloroquine retinopathy(2016 version).Ophthalmology, v.
123, n. 6, p. 1386-1394, 2016.
MELLES, R. B.; MARMOR, M. F. The risk of toxic
retinopathy in patients on long-term hydroxychloroquine therapy. JAMA
Ophthalmology, v. 132, n. 12, p. 1453-1460, 2014..
MCDUFFIE, F. C. Bone marrow depression after drug
therapy in patients with systemic lupus erythematosus. Annals of the Rheumatic
Diseases, v. 24, n. 3, p. 289-292, 1965.
ORNSTEIN, M. H.; SPERBER, K. The antiinflammatory and
antiviral effects of hydroxychloroquine in two patients with acquired
immunodeficiency syndrome and active inflammatory arthritis. Arthritis &
Rheumatism: Official Journal of the American College of Rheumatology, v. 39, n.
1, p. 157-161, 1996.
PANDYA, H. K. et al. Hydroxychloroquine retinopathy: a
review of imaging. Indian Journal of Ophthalmology, v. 63, n. 7, p. 570-574,
2015.
PEIRIS, J. S. M. et al. Coronavirus as a possible
cause of severe acute respiratory syndrome. The Lancet, v. 361, n. 9366, p.
1319-1325, 2003a.
PEIRIS, J. S. et al. Clinical progression and viral
load in a community outbreak of coronavirus-associated SARS pneumonia: a
prospective study. The Lancet, v.361, n.9371, p.1767-1772, 2003b.
PONTICELLI, C.; MORONI, G. Hydroxychloroquine in
systemic lupus erythematosus (SLE). Expert Opinion on Drug
Safety, v. 16, n. 3, p. 411–419, 2016.
RODRÍGUEZ-HURATDO, F. J.;
SÁEZ-MORENO, J. A.; RODRÍGUEZ-FERRER, J. M. Toxicidad ocular y recuperación
visual funcional en una paciente tratada con hidroxicloroquina. Reumatología Clínica, v. 11, n. 3, p. 170-173, 2015.
ROTHAN, H. A.; BYRAREDDY, S. N. The epidemiology and
pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of
Autoimmunity, p. 102433, 2020.
RUIZ-IRASTORZA, G. et al. Clinical efficacy and side
effects of antimalarials in systemic lupus erythematosus: a systematic review.
Annals of the Rheumatic Diseases, v. 69, n. 1, p. 20-28, 2010.
SAMES, E.; PATERSON, H.; LI, C.
Hydroxychloroquine-induced agranulocytosis in a patient with long-term
rheumatoid arthritis. European Journal of Rheumatology, v. 3, n. 2, p. 91-92,
2016.
SANDERS, J. M.; MONOGUE, M. L.; JODLOWSKI, T. Z.
Pharmacologic treatments for coronavirus disease 2019 (COVID-19) a review.
JAMA, 2020.
SAVARINO, A. et al. Effects of chloroquine on viral
infections: an old drug against today's diseases. The Lancet Infectious
Diseases, v. 3, n. 11, p. 722-727, 2003.
SHEIKHBAHAIE, F. et al. The effect of
hydroxychloroquine on glucose control and insulin resistance in the prediabetes
condition. Advanced Biomedical Research, v. 5, p. 145, 2016.
SHIPPEY, E. A.; WAGLER, V. D.; COLLAMER, A. N.
Hydroxychloroquine: an old drug with new relevance. Cleveland Clinic Journal of
Medicine, v. 85, n. 6, p. 459-467, 2018.
SHU, C. et al. Exploring Potential Super Infection in
SARS-CoV2 by Genome-Wide Analysis and Receptor–Ligand Docking. 2020.
SINGH, A. K. et al. Chloroquine and hydroxychloroquine
in the treatment of COVID-19 with or without diabetes: a systematic search and
a narrative review with a special reference to India and other developing
countries. Diabetes & Metabolic Syndrome: Clinical Research & Reviews,
2020.
SIMMONS, G. et al. Characterization of severe acute
respiratory syndrome-associated coronavirus (SARS-CoV) spike
glycoprotein-mediated viral entry. Proceedings of the National Academy of
Sciences, v. 101, n. 12, p. 4240-4245, 2004.
SHEIKHBAHAIE, F. et al. The effect of
hydroxychloroquine on glucose control and insulin resistance in the prediabetes
condition. Advanced Biomedical Research, v. 5, p. 145, 2016.
SHOJANIA, K.; KOEHLER, B. E.; ELLIOTT, T. Hypoglycemia
induced by hydroxychloroquine in a type II diabetic treated for polyarthritis.
The Journal of Rheumatology, v. 26, n. 1, p. 195-196, 1999.
SOHRABI, C. et al. World Health Organization declares
global emergency: A review of the 2019 novel coronavirus (COVID-19).
International Journal of Surgery, 2020.
TAHERIAN E. et al. The biological and clinical
activity of anti-malarial drugs in autoimmune disorders. Current Rheumatology
Reviews, v. 9, n. 1, p. 45-62, 2013.
TONNESMANN, E.; KANDOLF, R.; LEWALTER, T. Chloroquine
cardiomyopathy - a review of the literature. Immunopharmacology and
Immunotoxicology, v. 35, n. 3, p. 434-442, 2013.
TSANG, A. C. et al. The diagnostic utility of
multifocal electroretinography in detecting chloroquine and hydroxychloroquine
retinal toxicity. American Journal of Ophthalmology, v. 206, p. 132-139, 2019.
UL, Q. M. T. et al. Structural basis of SARS-CoV-2
3CLpro and anti-COVID-19 drug discovery from medicinal plants. Journal of
Pharmaceutical Analysis, 2020.
VIVEKANANTHAN, S. C. et al. Preliminary report of
anti-hepatitis C virus activity of chloroquine and hydroxychloroquine in
huh-5-2 cell line. Indian Journal of Pharmaceutical Sciences, v. 68, n. 4,
2006.
WANG, L. F. et al. Hydroxychloroquine-inhibited dengue
virus is associated with host defense machinery. Journal of Interferon &
Cytokine Research, v. 35, n. 3, p. 143-156, 2015.
WOLFE, F.; MARMOR, M. Rates and predictors of
hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and
systemic lupus erythematosus. Arthritis Care & Research, v. 62, n. 6, p.
775-784, 2010.
WU, S. F. et al. Hydroxychloroquine inhibits CD154
expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT,
but not STAT5, signaling. Arthritis Research & Therapy, v. 19, n. 1, p.
183, 2017.
XU, T. et al. Indomethacin has a potent antiviral
activity against SARS CoV-2 in vitro and canine coronavirus in vivo. bioRxiv,
2020.
XU, Y.; LI, X.; ZHU, B.; LIANG, H.; FANG, C.; GONG,
Y.; ZHANG, H. Characteristics of pediatric SARS-CoV-2 infection and potential
evidence for persistent fecal viral shedding. Nature Medicine, p. 1-4, 2020.
YAM, J. C.; KWOK, A. K. Ocular toxicity of
hydroxychloroquine. Hong Kong Medical Journal, v. 12, n. 4, p. 294-304, 2006.
YANG, X. et al. Clinical course and outcomes of
critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a
single-centered, retrospective, observational study. The Lancet Respiratory
Medicine, 2020.
YAO, X. et al. In vitro antiviral activity and
projection of optimized dosing design of hydroxychloroquine for the treatment
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical
Infectious Diseases, 2020.
YUSUF, I.H. et al. Hydroxychloroquine retinopathy. Eye
(Lond), v. 31, n. 6, p. 828-845, 2017.
ZHAO, H. et al. Hydroxychloroquine-induced
cardiomyopathy and heart failure in twins. Journal of Thoracic Disease, v. 10,
n. 1, p. E70-E73, 2018.
ZAKI, A. M. et al. A. Isolation of a novel coronavirus
from a man with pneumonia in Saudi Arabia. New England Journal of Medicine, v.
367, n. 19, p. 1814-1820, 2012.
ZHOU, D.; DAI, S. M.; TONG, Q. COVID-19: a
recommendation to examine the effect of hydroxychloroquine in preventing
infection and progression. Journal of Antimicrobial Chemotherapy, 2020.
ZHU, N. et al. China Novel Coronavirus Investigating
and Research Team. A novel coronavirus from patients with pneumonia in China,
2019. New England Journal of Medicine, v. 382, n. 8, p. 727-733, 2020.
ZUMLA, A.; HUI, D. S.; PERLMAN, S. Middle East
respiratory syndrome. Lancet, v. 386, n. 1, p. 995-1007, 2015.
Nenhum comentário:
Postar um comentário